

Stefano A Pileri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1452647/stefano-a-pileri-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers

10,568
citations

37
h-index

102
g-index

137
ext. papers

13,128
ext. citations

5.5
avg, IF

5.84
L-index

#	Paper	IF	Citations
124	Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls.. <i>Current Oncology</i> , 2022 , 29, 956-968	2.8	1
123	Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T-cell lymphoma.. <i>Cell Reports</i> , 2022 , 39, 110695	10.6	1
122	Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. <i>Cancer</i> , 2021 ,	6.4	3
121	A three-gene signature based on , and improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021 , 106, 2405-2416	6.6	4
120	Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas. <i>Cells</i> , 2021 , 10,	7.9	5
119	Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. <i>Blood</i> , 2021 , 138, 213-220	2.2	7
118	Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients. <i>European Journal of Cancer</i> , 2021 , 148, 277-286	7.5	1
117	HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis. <i>Diagnostics</i> , 2021 , 11,	3.8	1
116	HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases. <i>Biology</i> , 2021 , 10,	4.9	1
115	The Fundamentals of T-cell Lymphocyte Biology 2021 , 1-8		
114	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 6039-6053	12.9	3
113	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2). <i>Cancers</i> , 2021 , 13,	6.6	9
112	Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2021 , 13,	6.6	1
111	Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma. <i>Haematologica</i> , 2020 , 105, e432-e436	6.6	2
110	Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics. <i>Hematology/Oncology Clinics of North America</i> , 2020 , 34, 511-521	3.1	5
109	Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 259-267	5.1	9
108	Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101963	14.4	28

107	Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis. <i>Clinical Science</i> , 2020 , 134, 1151-1166	6.5	6
106	Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma: A Potential Diagnostic Pitfall. <i>American Journal of Surgical Pathology</i> , 2020 , 44, 657-664	6.7	10
105	A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. <i>IScience</i> , 2020 , 23, 101562	6.1	14
104	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. <i>Blood Advances</i> , 2020 , 4, 4124-4135	5.8	13
103	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. <i>Modern Pathology</i> , 2020 , 33, 179-187	9.8	11
102	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020 , 135, 534-541	2.2	37
101	Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. <i>Blood</i> , 2019 , 134, 2159-2170	2.2	45
100	Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas. <i>Human Pathology</i> , 2019 , 90, 60-69	3.7	14
99	Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. <i>Cancers</i> , 2019 , 11,	6.6	43
98	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019 , 185, 330-334	4.5	4
97	Novel markers in pediatric-type follicular lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 475, 771-779	5.1	15
96	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. <i>Journal of Clinical Oncology</i> , 2019 , 37, 611-611	2.2	3
95	A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS7575-TPS7575	2.2	1
94	Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients. <i>Blood</i> , 2019 , 134, 5289-5289	2.2	
93	B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in 18 Consecutive Patients from Two Italian Institutions. <i>Blood</i> , 2019 , 134, 1631-1631	2.2	
92	Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO). <i>Blood</i> , 2019 , 134, 5283-5283	2.2	
91	The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi. <i>Blood</i> , 2019 , 134, 2025-2025	2.2	
90	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019 , 133, 1664-1676	2.2	87

89	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. <i>Haematologica</i> , 2019 , 104, 729-737	6.6	33
88	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2904-2910	1.9	5
87	Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018 , 181, 760-769	4.5	26
86	slan Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. <i>Cancer Research</i> , 2018 , 78, 3544-3559	10.1	17
85	Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study. <i>Blood</i> , 2018 , 132, 5294-5294	2.2	2
84	Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. <i>Blood</i> , 2018 , 132, 4078-4078	2.2	1
83	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018 , 132, 789-789	2.2	2
82	Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial. <i>Blood</i> , 2018 , 132, 1627-1627	2.2	4
81	Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies. <i>Blood</i> , 2018 , 132, 676-676	2.2	1
80	Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi. <i>Blood</i> , 2018 , 132, 2902-2902	2.2	2
79	Dissecting diffuse large B-cell lymphomas of the "not otherwise specified" type: the impact of molecular techniques. <i>F1000Research</i> , 2018 , 7,	3.6	2
78	Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 180, 224-235	4.5	8
77	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. <i>Annals of Oncology</i> , 2018 , 29, 2363-2370	10.3	47
76	Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 473, 749-757	5.1	4
75	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 764-769	11.5	67
74	SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity-reply. <i>Human Pathology</i> , 2017 , 66, 238-239	3.7	
73	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017 , 4, e15-e23	14.6	75
72	B-cell lymphomas with discordance between pathological features and clinical behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 471, 439-451	5.1	4

71	Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 470, 575-582	5.1	16
70	Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma - Authors'Reply. <i>Lancet Haematology,the</i> , 2017 , 4, e64-e66	14.6	
69	Pathology of nodal marginal zone lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2017 , 30, 50-55	4.2	10
68	Understanding lymphoma molecular complexity. <i>Blood</i> , 2017 , 130, 1780-1781	2.2	2
67	The clinicopathologic spectrum of mature aggressive B cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 471, 453-466	5.1	19
66	Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 471, 467-489	5.1	38
65	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1076-1088	21.7	72
64	Cytotoxic Epstein-Barr virus-positive large B cell lymphoma: a regulatory B cell-derived neoplasia?. <i>Histopathology</i> , 2017 , 70, 650-656	7.3	
63	Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients. <i>Human Pathology</i> , 2017 , 59, 94-101	3.7	6
62	CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. <i>American Journal of Hematology</i> , 2017 , 92, E1-E2	7.1	22
61	The pathobiology and treatment of Hodgkin lymphoma. Where do we go from Gianni Bonadonna's lesson?. <i>Tumori</i> , 2017 , 103, 101-113	1.7	2
60	Primary bone lymphoma of the talus: a challenging diagnosis. <i>Tumori</i> , 2017 , 103, e62-e65	1.7	
59	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. <i>Oncotarget</i> , 2017 , 8, 111836-111846	3.3	32
58	Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. <i>Leukemia and Lymphoma</i> , 2016 , 57, 400-410	1.0	3
57	Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of "germinotropic" lymphoproliferative disorder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 468, 441-50	5.1	5
56	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 214-27	7	17
55	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 228-40	7	24
54	Arginase 1 is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 1770-1770	2.2	1

53	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016 , 128, 4096-4096	2.2	1
52	Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2016 , 128, 472-472	2.2	2
51	Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. <i>Oncotarget</i> , 2016 , 7, 224-40	3.3	28
50	VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016 , 128, 2741-2741		
49	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016 , 127, 2375-90	2.2	4080
48	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016 , 3, e467-e479	14.6	44
47	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4015-4022	2.2	49
46	miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's disease. <i>European Journal of Cancer</i> , 2016 , 64, 159-66	7.5	10
45	Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. <i>Cancer Cell</i> , 2015 , 27, 516-32	24.3	283
44	CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1. <i>Experimental Hematology</i> , 2015 , 43, 268-76.e5	3.1	6
43	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. <i>Blood</i> , 2015 , 125, 2530-43	2.2	96
42	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015 , 4, 24	7.8	3
41	BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients. <i>British Journal of Haematology</i> , 2015 , 170, 282-5	4.5	5
40	Follicular helper T-cell-related lymphomas. <i>Blood</i> , 2015 , 126, 1733-4	2.2	24
39	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 125	22.4	24
38	Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation. <i>BMC Cancer</i> , 2015 , 15, 668	4.8	21
37	Molecular Genetics of Peripheral T-cell Lymphomas 2015 , 1-9		
36	The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 171, 215-226	4.5	39

35	Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma. <i>PLoS Pathogens</i> , 2015 , 11, e1005158	158	74
34	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 6553-69	3-3	47
33	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. <i>Oncotarget</i> , 2015 , 6, 6544-52	3-3	27
32	A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2014 , 27, 1345-54	9.8	18
31	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014 , 123, 1293-6	2.2	255
30	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014 , 123, 2915-23	2.2	299
29	Pathobiology of hodgkin lymphoma. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014 , 6, e2014040	3.2	11
28	Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. <i>American Journal of Surgical Pathology</i> , 2014 , 38, e60-71	6.7	69
27	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7049-54	5.6	18
26	Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3019-25	2.2	102
25	Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. <i>Journal of Clinical Oncology</i> , 2013 , 31, 240-6	2.2	216
24	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. <i>Haematologica</i> , 2013 , 98, 239-46	6.6	197
23	CD30 expression in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013 , 98, e81-2	6.6	83
22	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. <i>Nature Medicine</i> , 2012 , 18, 1699-704	50.5	85
21	Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. <i>Histopathology</i> , 2012 , 61, 33-46	7.3	27
20	New molecular insights into peripheral T cell lymphomas. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3448-55	15.9	33
19	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , 2011 , 117, 5019-32	2.2	1356
18	Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive. <i>Histopathology</i> , 2011 , 59, 679-91	7.3	40

17	Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennert's lymphoma nowadays?. <i>Histopathology</i> , 2011 , 59, 1173-82	7.3	28
16	Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood</i> , 2011 , 117, 3402-8	2.2	290
15	Pathobiology of ALK-negative anaplastic large cell lymphoma. <i>Mental Illness</i> , 2011 , 3 Suppl 2, e5	0.9	7
14	Identification of Differentially Expressed miRNAs in Peripheral t-Cell Lymphomas. <i>Blood</i> , 2011 , 118, 773-773		
13	Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2011 , 118, 880-880	2.2	0
12	The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. <i>Haematologica</i> , 2010 , 95, 432-9	6.6	84
11	Novel markers of normal and neoplastic human plasmacytoid dendritic cells. <i>Blood</i> , 2008 , 111, 3778-92	2.2	173
10	Expression of CD52 in peripheral T-cell lymphoma. <i>Haematologica</i> , 2007 , 92, 566-7	6.6	57
9	Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. <i>Blood</i> , 2007 , 110, 2316-23	2.2	260
8	Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. <i>Journal of Clinical Investigation</i> , 2007 , 117, 823-34	15.9	228
7	Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2472-9	2.2	295
6	The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis. <i>Haematologica</i> , 2005 , 90, 293	6.6	
5	Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. <i>Haematologica</i> , 2005 , 90, 341-7	6.6	40
4	Histopathology of B-cell chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004 , 18, 807-26, viii	3.1	6
3	A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. <i>Blood</i> , 2000 , 95, 2084-2092	2.2	366
2	Immunohistochemistry of bone-marrow biopsy. <i>Leukemia and Lymphoma</i> , 1997 , 26 Suppl 1, 69-75	1.9	10
1	Prognostic factors and survival in non-Hodgkin's lymphomas: the experience of the Istituto Oncologico Romagnolo (IOR). <i>Leukemia and Lymphoma</i> , 1994 , 14, 475-82	1.9	1